Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | GPR68 | Q15743 | 5/20 | 0.68 |
| ▸ | APP | P05067 | 2/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | DHFR | P00374 | 1/20 | 0.53 |
| ▸ | TPH1 | P17752 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9247173 | 0.98 | NPSR1 (0.72) | NPSR1GPR68APPADORA2AHTR2B | |
| SCHEMBL6727019 | 0.96 | NPSR1 (0.74) | NPSR1GPR68APPADORA2AHTR2B | |
| SCHEMBL14869402 | 0.87 | NPSR1 (0.64) | NPSR1GPR68APPADORA2AHTR2B | |
| SCHEMBL14869439 | 0.87 | GAA (0.71) | NPSR1GPR68APPADORA2AHTR2B | |
| SCHEMBL29609599 | 0.87 | NPSR1 (0.64) | NPSR1GPR68APPADORA2AHTR2B | |
| SCHEMBL3298289 | 0.84 | KCNH3 (0.73) | NPSR1APPKCNH3GAARAD52 | |
| SCHEMBL14869452 | 0.83 | NPSR1 (0.59) | NPSR1GPR68APPADORA2AHTR2B | |
| SCHEMBL11819405 | 0.83 | NPSR1 (0.59) | NPSR1GPR68ADORA2AHTR2BSMN1; SMN2 | |
| SCHEMBL8058873 | 0.83 | NPSR1 (0.59) | NPSR1GPR68APPADORA2AHTR2B | |
| SCHEMBL11815396 | 0.83 | NPSR1 (0.59) | NPSR1GPR68APPADORA2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040200993-A1 | Reactive liquid polymer crosslinking agent and process for preparation | LCB WORLDWIDE, INC. | 2004-10-14 | — | — | US | claimed |
| US-20030168629-A1 | Reactive liquid polymer crosslinking agent and process for preparation | LCB WORLDWIDE, INC. | 2003-09-11 | — | — | US | claimed |
| CN-118702912-A | Preparation method of spontaneously degradable cyclic poly (ester-peptide), product and degradation method thereof | 浙江大学 | 2024-09-27 | — | — | CN | disclosed |
| US-20230312921-A1 | LOW-MOLD DEPOSIT HALOGEN-FREE FLAME-RETARDANT THERMOPLASTIC POLYAMIDE COMPOSITION, AND PREPARATION METHOD AND USE THEREOF | KINGFA SCI. & TECH.CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| EP-4227366-A1 | LOW-MOLD DEPOSIT HALOGEN-FREE FLAME-RETARDANT THERMOPLASTIC POLYAMIDE COMPOSITION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Kingfa Sci. & Tech. Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2019-03-14 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| EP-0903626-A1 | Amino-triazine compounds for (photo)thermographic materials | AGFA-GEVAERT N.V. (BE) | 1999-03-24 | — | — | EP | disclosed |
| EP-0789673-B1 | METHODS OF COAGULATING AND DECOLORIZING WASTE STREAMS | CYTEC TECH CORP (US) | 1998-12-16 | — | — | EP | disclosed |
| US-5807496-A | WATER TREATMENT; DEINKING | CYTEC TECHNOLOGY CORP. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5792867-A | Method of alkylating of triazine derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-08-11 | — | — | US | disclosed |
| US-5707532-A | RESULTING FROM PAPER RECYCLING, DEINKING, AMINO RESIN AND POLYAMINE FROM EPICHLOROHYDRIN AND DIMETHYLAMINE | CYTEC TECHNOLOGY CORP. (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0789673-A1 | METHODS OF COAGULATING AND DECOLORIZING WASTE STREAMS | CYTEC TECHNOLOGY CORP. (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0760369-A1 | PROCESS FOR ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-03-05 | — | — | EP | disclosed |
| EP-0711760-A1 | METHOD OF ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
| WO-1996013464-A1 | METHODS OF COAGULATING AND DECOLORIZING WASTE STREAMS | CYTEC TECHNOLOGY CORPORATION (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | NPSR1 2780/4885GPR68 2553/4885APP 2243/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | NPSR1 2780/4885GPR68 2553/4885APP 2243/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | NPSR1 2780/4885GPR68 2553/4885APP 2243/4885 |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | NPSR1 2780/4885GPR68 2553/4885APP 2243/4885 |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | NPSR1 2780/4885GPR68 2553/4885APP 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.